Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: A pilot phase II study

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5501-5506

  Tai, Cheng Jeng ^a,b   Chen, Ching Shyang ^a,b   Hung, Chin Sheng ^a,b   Kuo, Li Jen ^a,b   Wei, Po Li ^a,b   Chiou, Jeng Feng ^a   Hsu, Chung Huei ^a   Chiou, Hung Yi ^c   Wu, Chih Hsiung ^d  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bevacizumab; Breast cancer; Cisplatin; Docetaxel; HER2 negative; Metastatic

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ALLERGY; ANOREXIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; LUNG METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UROGENITAL TRACT HEMORRHAGE; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; TAXOIDS;

EID: 84872660072     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Miller KD, Sweeney CJ and Sledge GW Jr.: Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001.
2. Moy B and Goss PE: Lapatinib: Current Status and Future Directions in Breast Cancer. Oncologist 11: 1047-1057, 2006.
3. Chu E: Bevacizumab targeted therapy. Validation of angiogenesis as a key target for advanced colorectal cancer. Clin Colorectal Cancer 4: 16, 2004.
4. Eniu A: Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. J B.U.On. Suppl 1: S119-126, 2007.
5. Caprioni F and Fornarini G: Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncol 3: 141-148, 2007.
6. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ and Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clinl Oncol 24: 217-227, 2006.
7. Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A and Bangemann N: Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes. J Clin Oncol 25: 3246-3250, 2007.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 344: 783-792, 2001.
9. Koukourakis GV: Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question. Recent Pat Inflamm Allergy Drug Discov 6: 70-77, 2012.
10. Planchard D: Bevacizumab in non-small-cell lung cancer: a review. Expert Rev Anticancer Ther 11(8): 1163-1179, 2011.
11. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K: Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 25(3): 159-169, 2011.
12. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F and Isacoff W: Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 8(Suppl 1): s50-52, 2004.
13. Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335, 2005.
14. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase I/II doseescalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16): 117-124, 2003.
15. Link JS, Waisman JR, Nguyen B and Jacobs CL: Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 7: 779-783, 2007.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS and Rubinstein L: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
17. Therneau T and Grambsch P: Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
18. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 2003.
19. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators: Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 22(2): 301-306, 2011.
20. Miller KD: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3: 421-422, 2003.
21. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V and Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
22. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
23. Xu BH, Jiang ZF, Shen ZZ, Guan ZZ, Chen ZD, Cheng Y, Zheng H, Jiang J, Wang XJ, Tong ZS, Qin SK, Luo Y, Yao M, Wang LW and He J: Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study. Chin Med J (Engl) 125(5): 764-769, 2012.
24. Mayer EL, Lin NU and Burstein HJ: Novel approaches to advanced breast cancer. bevacizumab and lapatinib. J Natl Compr Canc Netw 5: 314-323, 2007.
25. Goldfarb SB, Hudis C and Dickler MN: Bevacizumab in metastatic breast cancer: when may it be used? Ther Adv Med Oncol 3 (2): 85-93, 2011.
26. Miles DW, Chan A, Dirix LY, Corte's J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A and Romieu G: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20): 3239-3247, 2010.
27. Montero AJ, Escobar M, Lopes G, Glück S and Vogel C: Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 14: 1-11, 2012.
28. Chu TB, Liu TC, Chen CS, Tsai YW and Chiu WT: Household out-of-pocket medical expenditures and national health insurance in Taiwan: income and regional inequality. BMC Health Serv Res 5: 60, 2005.
29. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P and Szucs TD: Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 45(8): 1397-1406, 2009.
30. D'Agostino RB Sr: Changing end points in breast-cancer drug approval - the Avastin story. N Engl J Med 14: 365(2): e2, 2011.